Last reviewed · How we verify
HS-10384 tablet Dose 1
At a glance
| Generic name | HS-10384 tablet Dose 1 |
|---|---|
| Sponsor | Hansoh BioMedical R&D Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HS-10384 tablet Dose 1 CI brief — competitive landscape report
- HS-10384 tablet Dose 1 updates RSS · CI watch RSS
- Hansoh BioMedical R&D Company portfolio CI